Pancreatic Cancer Research

ResearcherOdense University HospitalActive in the last 2 years

Claus Wilki Fristrup

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2721-0967; OpenAlex author ID A5070827313. Sources: OpenAlex.

Their work

Papers
31 (first author 6, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
72
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: 3 papers · 2019: 4 papers · 2020: 2 papers · 2021: 5 papers · 2022: 3 papers · 2023: 1 paper · 2024: 4 papers · 2025: 4 papers · 2026: 3 papers

Papers 31

  1. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for pancreatic cancer peritoneal metastases: A retrospective multicentric study from the ISSPP PIPAC D… Co-author DOI 10.1016/j.ejso.2026.112078↗
  2. Circulating tumour DNA as a prognostic tool for surgically treated pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.humpath.2025.106024↗
  3. Danish Pancreatic Cancer Group consensus guidelines on the management of pancreatic IPMN. First author DOI 10.1177/02841851261477089↗
  4. Symptom burden and quality of life in patients with pancreatic and peri-pancreatic cancer at admission to specialized palliative care: a nationwide register-ba… Co-author DOI 10.1007/s00520-025-10212-6↗
  5. Utility of peritoneal fluid for multiplexed mRNA profiling of peritoneal metastasis from pancreatic cancer. Co-author DOI 10.1016/j.prp.2025.156250↗
  6. Preoperative EUS-guided biopsy does not affect survival in patients with pancreatic cancer: A nationwide cohort study. First author DOI 10.1097/eus.0000000000000156↗
  7. Validity of the Pancreatic Cancer Registry in Southern Denmark. Last author DOI 10.61409/a08240545↗
  8. Exploring the prognostic value of circular RNAs in pancreatic ductal adenocarcinoma using genome-wide expression profiling. Co-author DOI 10.1016/j.pan.2024.04.004↗
  9. Prognostic value of margin clearance in total and distal pancreatectomy specimens with pancreatic ductal adenocarcinoma in a Danish population-based nationwide… First author DOI 10.1016/j.prp.2023.155077↗
  10. Effect of surgery versus chemotherapy in pancreatic cancer patients: a target trial emulation. Co-author DOI 10.1093/jnci/djae024↗
  11. RNA expression profiling of peritoneal metastasis from pancreatic cancer treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). Co-author DOI 10.1515/pp-2024-0001↗
  12. Prognostic significance of margin clearance in pancreaticoduodenectomy specimens with pancreatic ductal adenocarcinoma in a Danish population-based nationwide … First author DOI 10.1016/j.hpb.2023.03.016↗
  13. Healthcare use in the year preceding a diagnosis of pancreatic cancer: a register-based cohort study in Denmark. Co-author DOI 10.1080/02813432.2022.2069730↗
  14. Disparity in use of modern combination chemotherapy associated with facility type influences survival of 2655 patients with advanced pancreatic cancer. Last author DOI 10.1080/0284186x.2021.2012252↗
  15. Long-Term Outcomes of Venous Resections in Pancreatic Ductal Adenocarcinoma Patients: A Nationwide Cohort Study. Co-author DOI 10.1097/as9.0000000000000219↗
  16. Intra-observer agreements in multidisciplinary team assessments of pancreatic cancer patients. Co-author DOI 10.1002/jso.26670↗
  17. Gene expression profiling of morphologic subtypes of pancreatic ductal adenocarcinoma using surgical and EUS-FNB specimens. Co-author DOI 10.1016/j.pan.2021.01.025↗
  18. Value of regular endosonography and [18F]fluorodeoxyglucose PET-CT after surgery for gastro-oesophageal junction, stomach or pancreatic cancer. Co-author DOI 10.1093/bjsopen/zraa028↗
  19. Patterns of Palliative Chemotherapy and Survival in Patients With Pancreatic Cancer Focusing on Age: A Nationwide Real-World Danish Registry Study. First author DOI 10.1097/mpa.0000000000001833↗
  20. Next-generation sequencing and histological response assessment in peritoneal metastasis from pancreatic cancer treated with PIPAC. Co-author DOI 10.1136/jclinpath-2020-206607↗
  21. Initial treatment and survival in 4163 Danish patients with pancreatic cancer: A nationwide unselected real-world register study. First author DOI 10.1016/j.ejca.2020.01.015↗
  22. Regional and socio-economic variation in survival after a pancreatic cancer diagnosis in Denmark. Co-author PMID 32053483↗
  23. Multicentre study of multidisciplinary team assessment of pancreatic cancer resectability and treatment allocation. Co-author DOI 10.1002/bjs.11093↗
  24. Waiting time to surgery and pancreatic cancer survival: A nationwide population-based cohort study. Last author DOI 10.1016/j.ejso.2019.05.029↗
  25. The effect of postoperative gemcitabine on overall survival in patients with resected pancreatic cancer: A nationwide population-based Danish register study. Last author DOI 10.1080/0284186x.2019.1581374↗
  26. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Co-author DOI 10.1136/gutjnl-2017-314828↗
  27. Value of anti-plasminogen binding peptide, anti-carbonic anhydrase II, immunoglobulin G4, and other serological markers for the differentiation of autoimmune p… Co-author DOI 10.1097/md.0000000000011641↗
  28. Urban versus rural residency and pancreatic cancer survival: A Danish nationwide population-based cohort study. Co-author DOI 10.1371/journal.pone.0202486↗
  29. Regional variation in surgery for pancreatic cancer in Denmark 2011-2015. Co-author PMID 30187862↗
  30. Danish Pancreatic Cancer Database. Co-author DOI 10.2147/clep.s99471↗
  31. [Danish Pancreatic Cancer Database]. Co-author PMID 23079448↗

Closest collaborators

The 25 strongest of 72 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Bau Mortensen · 19 shared papers, 2012–2026 · strength 3.25
  2. Sönke Detlefsen · 14 shared papers, 2016–2026 · strength 2.51
  3. Per Pfeiffer · 12 shared papers, 2019–2026 · strength 2.05
  4. Frank Viborg Mortensen · 10 shared papers, 2018–2026 · strength 1.45
  5. Jakob Kirkegård · 7 shared papers, 2018–2025 · strength 1.03
  6. Carsten Palnæs Hansen · 8 shared papers, 2012–2025 · strength 0.93
  7. Trine Aaquist · 3 shared papers, 2023–2026 · strength 0.67
  8. Morten Bækbo Ladekarl · 7 shared papers, 2012–2022 · strength 0.65
  9. Henriette Engberg · 3 shared papers, 2020–2025 · strength 0.64
  10. Martin Graversen · 3 shared papers, 2021–2025 · strength 0.61
  11. Inna Markovna Chen · 2 shared papers, 2022–2025 · strength 0.47
  12. Louise S. Rasmussen · 4 shared papers, 2019–2022 · strength 0.42
  13. Mogens Tornby Stender · 2 shared papers, 2022–2025 · strength 0.42
  14. Caroline Ewertsen · 1 shared paper, 2026 · strength 0.39
  15. Bahareh Abdolalizadeh · 1 shared paper, 2026 · strength 0.39
  16. Cara Manmeet Bhuller · 1 shared paper, 2025 · strength 0.37
  17. Britta Weber · 3 shared papers, 2020–2022 · strength 0.34
  18. Lukas Gammelgaard Rasmussen · 2 shared papers, 2021–2024 · strength 0.34
  19. Thukirtha Chelliah · 1 shared paper, 2025 · strength 0.33
  20. Mathilde Adsersen · 1 shared paper, 2025 · strength 0.33
  21. Henrik Møller · 2 shared papers, 2020–2022 · strength 0.27
  22. Fabio Pacelli · 1 shared paper, 2026 · strength 0.27
  23. Andrea Di Giorgio · 1 shared paper, 2026 · strength 0.27
  24. Peter Vilmann · 1 shared paper, 2025 · strength 0.26
  25. Bojan Kovacevic · 1 shared paper, 2025 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.